GlassScriptPhysician profile
Jodi L Chitwood
NPI 1811050933
$6,025.11
in general payments reported to CMS, 2019-2025
37 companies · $1,796 in 2025
The $1,796 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.57 · 2021: $366 · 2022: $904 · 2023: $1,290 · 2024: $1,650 · 2025: $1,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,736.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $934.78 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $701.47 | 2022-2025 | |
| Abbvie INC. | $620.52 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $560.60 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $364.47 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $240.91 | 2021-2025 | Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $233.88 | 2022 | |
| Paratek Pharmaceuticals, INC. | $188.48 | 2021-2025 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $183.92 | 2022-2024 | Quviviq |
| Abbott Laboratories | $164.71 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $154.21 | 2024-2025 | Repatha, Krystexxa, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.89 | 2021-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $144.14 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $142.13 | 2024-2025 | |
| Exact Sciences Corporation | $132.44 | 2023-2025 | Cologuard Collection Kit |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Chitwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.